Clinical trial
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients With Relapsed or Refractory NHL or CLL
NCT05515406 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients With Relapsed or Refractory NHL or CLL
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 13, 2023
- Completion date
- August 13, 2025
- Enrollment
- 9 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.